Baclofen for alcohol abuse
Pro Research Analysisby 
Searched over 200M research papers
Baclofen for Alcohol Abuse: Efficacy and Safety
Introduction to Baclofen and Alcohol Use Disorder (AUD)
Alcohol use disorder (AUD) is a prevalent psychiatric condition with significant psychophysical, affective, and cognitive consequences. Baclofen, a GABA(B) receptor agonist, has been explored as a potential pharmacotherapy for AUD. This article synthesizes findings from multiple studies to evaluate the efficacy and safety of baclofen in treating alcohol dependence.
Efficacy of Baclofen in Reducing Alcohol Consumption
Mixed Results from Clinical Trials
Several randomized controlled trials (RCTs) have investigated baclofen's efficacy in reducing alcohol consumption, yielding mixed results. A study conducted in Israel found no significant difference between baclofen and placebo in reducing heavy drinking days or increasing abstinent days, although both groups showed reduced distress, depression, and craving levels1. Similarly, a U.S. study reported no significant differences in heavy drinking days or abstinent days between baclofen and placebo groups, despite a reduction in anxiety levels among baclofen users2.
Meta-Analyses and Systematic Reviews
Meta-analyses provide a broader perspective on baclofen's efficacy. One meta-analysis indicated that baclofen significantly increased time to lapse and the percentage of patients abstinent at the endpoint, particularly among heavy drinkers. However, high-dose baclofen was not necessarily more effective than low-dose baclofen and had lower tolerability3. Another meta-analysis concluded that baclofen was associated with higher abstinence rates but did not significantly impact heavy drinking days, craving, anxiety, or depression9.
Safety and Tolerability of Baclofen
Adverse Events and Tolerability
The safety profile of baclofen varies with dosage. High-dose baclofen (up to 300 mg/day) has been associated with more frequent adverse events such as drowsiness, fatigue, and insomnia, although serious adverse events were rare8. A systematic review highlighted that while baclofen increased the risk of certain adverse events like vertigo, somnolence, and muscle spasms, it did not significantly differ from placebo in terms of overall adverse events or dropout rates due to adverse events4.
High-Dose Baclofen: A Potential Second-Line Treatment
Individualized High-Dose Baclofen
High-dose baclofen, titrated to individual needs, has shown promise in some studies. The Bacloville trial, a large French RCT, found that individualized high-dose baclofen significantly reduced alcohol consumption to low-risk levels compared to placebo, although the study faced challenges such as high dropout rates and complex statistical interpretations7 8. Another study reported that high-dose baclofen (up to 270 mg/day) effectively supported abstinence and was well-tolerated, even in cases of relapse5.
Conclusion
The efficacy of baclofen in treating alcohol dependence remains inconclusive, with studies showing mixed results. While some meta-analyses and high-dose trials suggest potential benefits, particularly among heavy drinkers, the overall evidence does not firmly establish baclofen as a superior treatment compared to placebo. Safety concerns, especially at higher doses, further complicate its use. More rigorous, large-scale RCTs are needed to clarify baclofen's role in AUD treatment and identify patient subgroups that may benefit the most.
Sources and full results
Most relevant research papers on this topic
Baclofen as add-on to standard psychosocial treatment for alcohol dependence: a randomized, double-blind, placebo-controlled trial with 1 year follow-up.
Baclofen showed no evidence of superiority over placebo in treating alcohol dependence, but improved health-related quality of life and reduced distress, depression, and cravings.
RCT
Highly CitedEfficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.
Baclofen showed no evidence of superiority to placebo in treating alcohol dependence, but did significantly reduce state anxiety.
RCT
Rigorous JournalHighly CitedEfficacy, tolerability, and safety of low-dose and high-dose baclofen in the treatment of alcohol dependence: A systematic review and meta-analysis
Baclofen is effective in treating alcohol dependence, especially among heavy drinkers, with low-dose 30-60 mg showing better efficacy than high-dose >60 mg/day.
Meta-AnalysisHighly CitedBaclofen for alcohol use disorder.
Baclofen is ineffective for achieving and maintaining abstinence or reducing alcohol consumption in people with alcohol use disorder compared to placebo.
Meta-Analysis
Very Rigorous JournalHighly CitedHigh-dose baclofen for the treatment of alcohol dependence (BACLAD study): A randomized, placebo-controlled trial
Individually titrated high-dose baclofen effectively supported alcohol-dependent patients in maintaining abstinence and showed high tolerability, even in the event of relapse.
RCTHighly CitedBaclofen for alcohol use disorder.
Baclofen may decrease the risk of relapse in people with alcohol use disorder compared to placebo.
Meta-AnalysisIndividualized, High-Dose Baclofen for Reduction in Alcohol Intake in Persons With High Levels of Consumption.
Individualized high-dose baclofen may be a useful second-line approach for heavy drinkers to reduce alcohol intake, particularly in patients with liver disease.
Meta-AnalysisTitrated baclofen for high-risk alcohol consumption: A randomized placebo-controlled trial in outpatients with one-year follow up.
Titrated baclofen effectively reduces high-risk alcohol consumption to low-risk levels, but has a higher number of adverse events and more serious side effects.
RCT
Large Human TrialRigorous JournalBaclofen: its effectiveness in reducing harmful drinking, craving, and negative mood. A meta‐analysis
Baclofen increases abstinence rates in alcohol use disorders, but does not significantly reduce heavy drinking, cravings, anxiety, or depression.
Meta-AnalysisHighly CitedBaclofen in the treatment of alcohol dependence with or without liver disease: multisite, randomised, double-blind, placebo-controlled trial
Baclofen may be an effective treatment option for alcohol dependence in patients with alcoholic liver disease, but its role may be limited to specialist services due to potential adverse events.
RCTRigorous JournalHighly Cited